

**Table 4.2**  
**Counts (Annualized Percentages) of Participants with Self-Reported Outcomes by Age at Enrollment and Race/Ethnicity for SRC Super Cohort Participants<sup>1</sup> Who Did Not Report a Prevalent Condition at Baseline**

Data as of: March 31, 2018; Events through March 31, 2018

Outcome	Total	Age at Enrollment			
		50-54	55-59	60-69	70-79
<b>Number randomized</b>	117634	14781	22638	53171	27044
<b>Mean follow-up (months)</b>	188.0	213.7	208.8	189.5	153.5
DVT	3913 (0.22%)	328 (0.13%)	603 (0.16%)	1950 (0.24%)	1032 (0.31%)
Pulmonary embolism <sup>2</sup>	2450 (0.13%)	213 (0.08%)	420 (0.11%)	1250 (0.15%)	567 (0.17%)
Diabetes (treated)	15659 (0.87%)	2081 (0.80%)	3267 (0.85%)	7416 (0.91%)	2895 (0.87%)
Hysterectomy	6587 (0.60%)	1021 (0.63%)	1589 (0.63%)	3018 (0.62%)	959 (0.49%)
Osteoarthritis <sup>3</sup>	36588 (3.35%)	5593 (2.91%)	8182 (3.12%)	16449 (3.48%)	6364 (3.83%)
Intestinal polyps	29529 (1.75%)	4462 (1.77%)	6829 (1.84%)	13497 (1.78%)	4741 (1.58%)
Lupus	1887 (0.10%)	242 (0.09%)	390 (0.10%)	874 (0.10%)	381 (0.11%)
Pills for hypertension	44295 (3.23%)	5557 (2.48%)	8991 (2.84%)	20525 (3.39%)	9222 (4.12%)
COPD <sup>4</sup>	6420 (0.90%)	720 (0.74%)	1328 (0.91%)	3414 (1.07%)	958 (0.70%)
Macular degeneration <sup>5</sup>	15740 (1.29%)	1079 (0.63%)	2254 (0.88%)	8058 (1.45%)	4349 (1.91%)
Alzheimer's disease <sup>5</sup>	11119 (0.91%)	432 (0.25%)	1120 (0.44%)	5747 (1.04%)	3820 (1.67%)
Parkinson's disease <sup>5</sup>	2031 (0.17%)	131 (0.08%)	344 (0.13%)	1148 (0.21%)	408 (0.18%)

Outcomes	Race/Ethnicity			
	American Indian/ Alaskan Native	Asian/Pacific Islander	White	Unknown
<b>Number randomized</b>	583	3663	111511	1877
<b>Mean follow-up (months)</b>	156.8	161.5	189.4	166.3
DVT	11 (0.15%)	34 (0.07%)	3816 (0.23%)	52 (0.21%)
Pulmonary embolism <sup>2</sup>	9 (0.12%)	17 (0.03%)	2400 (0.14%)	24 (0.09%)
Diabetes (treated)	106 (1.55%)	522 (1.11%)	14746 (0.86%)	285 (1.14%)
Hysterectomy	15 (0.41%)	120 (0.38%)	6364 (0.61%)	88 (0.57%)
Osteoarthritis <sup>3</sup>	148 (3.51%)	1146 (3.24%)	34716 (3.35%)	578 (3.59%)
Intestinal polyps	123 (1.77%)	749 (1.68%)	28232 (1.76%)	425 (1.81%)
Lupus	15 (0.20%)	40 (0.08%)	1800 (0.10%)	32 (0.12%)
Pills for hypertension	185 (3.72%)	1180 (3.39%)	42263 (3.22%)	667 (3.61%)
COPD <sup>4</sup>	30 (0.90%)	85 (0.37%)	6226 (0.92%)	79 (0.71%)
Macular degeneration <sup>5</sup>	50 (0.86%)	236 (0.62%)	15276 (1.32%)	178 (0.95%)
Alzheimer's disease <sup>5</sup>	41 (0.71%)	194 (0.51%)	10725 (0.92%)	159 (0.85%)
Parkinson's disease <sup>5</sup>	7 (0.12%)	31 (0.08%)	1960 (0.17%)	33 (0.18%)

<sup>1</sup> The SRC Super Cohort includes all White, American Indian/Alaskan Native, Asian/Pacific Islander, and Unknown Race/Ethnicity participants from the Dietary Modification Trial (not also in the Hormone Trial) and the Observational Study.

<sup>2</sup> During the main WHI Study and the WHI Extension Study 2005-2010, pulmonary embolism includes only inpatient self-reports. During WHI Extension Study 2010-2020, pulmonary embolism includes both inpatient and outpatient self-reports.

<sup>3</sup> This outcome has not been self-reported on all versions of Form 33 during WHI follow-up. The annualized percentages are corrected for the different amounts of follow-up.

<sup>4</sup> Data only collected during the WHI Extension Study 2010-2020.

<sup>5</sup> Data only collected during the WHI Extension Studies 2005-2020.